Tikomed

About Us

TikoMed is a privately held pharmaceutical company based in Sweden. TikoMed is developing innovative treatments for neurodegenerative diseases and other degenerative conditions through its drug candidate ILB®, a dextran sulfate that has shown a good safety profile and promising results for the treatment of ALS in limited phase 2a studies. For more information, see www.tikomed.com.

Links

TIKOMED AB

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

TikoMed signs letter of intent with Karolinska Institutet on myocardial infarction study

Wed, Feb 25, 2026 11:34 CET

The Department of Medicine Solna at Karolinska Institutet and TikoMed AB have signed a letter of intent for a collaboration on a clinical study of ILB[®] in myocardial infarction.PRESS RELEASE Stockholm 25 February, 2026 The Department of Medicine Solna at Karolinska Institutet and TikoMed AB have signed a letter of intent for a collaboration on a clinical study of ILB® in myocardial infarction. The study is called ILBIAMI and the aim is to evaluate the effect of ILB® in counteracting the consequences of myocardial infarction by limiting the extent of heart muscle damage.

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Links

TikoMed signs letter of intent with Karolinska Institutet on myocardial infarction study

Subscribe